Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Arnel Tagle

Internal Medicine Baltimore, MD Medical Doctor

NPI 1881632354 CMS profile 311890

301 Saint Paul Pl, Phys Office Bldg., Suite 907, Baltimore, MD 21202

Open in the dashboard

General payments

$2,011

121 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Arnel Tagle of Baltimore, MD is reported in the CMS Open Payments database as having received $2,011 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $373 21
2019 General $1,638 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arnel Tagle
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Arnel Tagle were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Arnel Tagle Internal Medicine median Middle half National median
2019 $1,638 $159 $48–$570 $163
2020 $373 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. AstraZeneca Pharmaceuticals LP $394 23 payments
  2. Novo Nordisk Inc $265 18 payments
  3. Pfizer Inc. $188 12 payments
  4. Sanofi-Aventis U.S. LLC $171 10 payments
  5. Merck Sharp & Dohme Corporation $146 13 payments
  6. Amgen Inc. $136 6 payments
  7. Lilly USA, LLC $126 8 payments
  8. GlaxoSmithKline, LLC. $71 4 payments
  9. Kowa Pharmaceuticals America, Inc. $69 4 payments
  10. Novartis Pharmaceuticals Corporation $66 3 payments
  11. Other $379 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $2,011 121 payments
Products named General payments · program years 2019–2020
  1. FARXIGA $213 10 payments
  2. Ozempic $187 12 payments
  3. CHANTIX $136 8 payments
  4. STEGLATRO $131 12 payments
  5. JANUVIA $131 12 payments
  6. ELIQUIS $127 7 payments
  7. BEVESPI AEROSPHERE $124 9 payments
  8. TRULICITY $115 7 payments
  9. JARDIANCE $115 7 payments
  10. JANUMET $97 9 payments
  11. Other $1,850 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,436

Median for Internal Medicine: 777

Drug cost

$137,775

Median for Internal Medicine: $73,373

Branded share of claims

15.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 17 $24,699
Eliquis Apixaban Brand 15 $22,723
Januvia Sitagliptin Phosphate Brand 15 $20,976
Mounjaro Tirzepatide Brand 15 $20,862
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $18,751
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 11 $4,897
Pravastatin Sodium Generic 66 $3,053
Rosuvastatin Calcium Generic 95 $2,354
Amlodipine Besylate Generic 190 $2,169
Metoprolol Succinate Generic 60 $1,783

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$30,506

Of which drugs: $3,710

Medicare patients

112

Average age 73

Services billed

487

64 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 29%
Arthritis 28%
Cancer 23%
COPD 21%
Depression 18%
Chronic kidney disease 17%
Ischemic heart disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 22 22 $1,800

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record